This global, open-label, randomized, Phase Ib/II trial enrolled patients with one of the following cancers: pancreatic ductal adenocarcinoma (PDAC), gastric or gastro-esophageal junction cancers (GC/GEJ), hormone receptor-positive or triple-negative breast cancers (HR+/TNBC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC). This evidence concerns the gene NR4A1 and non-small cell lung carcinoma.